Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $9.12.

Several research analysts have commented on AUTL shares. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, October 8th. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Finally, Wells Fargo & Company dropped their target price on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Marex Group plc acquired a new position in shares of Autolus Therapeutics in the second quarter valued at approximately $28,000. R Squared Ltd purchased a new position in Autolus Therapeutics during the second quarter worth about $50,000. Delaney Dennis R acquired a new stake in Autolus Therapeutics in the second quarter valued at about $55,000. Forefront Wealth Management Inc. acquired a new stake in Autolus Therapeutics in the second quarter valued at about $61,000. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in Autolus Therapeutics by 63.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 30,432 shares of the company’s stock valued at $69,000 after purchasing an additional 11,821 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Stock Up 0.6%

AUTL opened at $1.56 on Thursday. The firm has a market cap of $415.18 million, a price-to-earnings ratio of -1.86 and a beta of 1.84. Autolus Therapeutics has a 52 week low of $1.11 and a 52 week high of $4.12. The business’s 50 day moving average is $1.53 and its two-hundred day moving average is $1.81.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million. Equities analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.